Literature DB >> 15122588

Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer.

Tadeusz Debniak1, Bohdan Górski, Rodney J Scott, Cezary Cybulski, Krzysztof Medrek, Elzbieta Zowocka, Grzegorz Kurzawski, Boguslaw Debniak, Józef Kadny, Stanislawa Bielecka-Grzela, Romuald Maleszka, Jan Lubiński.   

Abstract

The CDKN2A/ARF genes have been associated with increased risk of malignant melanoma (MM) in families with multiple members affected by disease and in families characterized by the constellation of breast cancer and MM. The exact contribution of CDKN2A/ARF to disease risk remains poorly characterized, especially in diverse populations. In this report, the contribution of CDKN2A/ARF germline mutations and large rearrangements to disease in Polish familial MM (FMM) and aggregations of breast cancer and MM were assessed using a strategy that included genomic sequencing, restriction fragment length polymorphism and multiplex ligation-dependent probe amplification. We examined 16 FMM cases (group 1), 44 MM probands with a cancer family aggregation (CFA) that included at least one breast cancer (group 2) and 22 breast cancer probands with CFA and MM (group 3). The results revealed a paucity of mutations in CDKN2A/ARF, suggesting that in the Polish population this gene does not contribute significantly to either FMM or MM within the context of CFA. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122588     DOI: 10.1002/ijc.20163

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  A common variant of CDKN2A (p16) predisposes to breast cancer.

Authors:  T Debniak; B Górski; T Huzarski; T Byrski; C Cybulski; A Mackiewicz; S Gozdecka-Grodecka; J Gronwald; E Kowalska; O Haus; E Grzybowska; M Stawicka; M Swiec; K Urbański; S Niepsuj; B Waśko; S Góźdź; P Wandzel; C Szczylik; D Surdyka; A Rozmiarek; O Zambrano; M Posmyk; S A Narod; J Lubinski
Journal:  J Med Genet       Date:  2005-05-06       Impact factor: 6.318

2.  Malignant melanoma and breast carcinoma: a bidirectional correlation.

Authors:  W L Ho; H Comber; A D K Hill; G M Murphy
Journal:  Ir J Med Sci       Date:  2009-03-05       Impact factor: 1.568

Review 3.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

4.  Two cancers in one: breast carcinoma with underlying melanoma.

Authors:  Nicholas A Douville; Elizabeth A Sakach; Elizabeth A Wiewiorowski; William Herlihy; John E Pippen
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

5.  Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers.

Authors:  Xiaofeng Dai; Yang Li; Zhonghu Bai; Xu-Qing Tang
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379

6.  Familial malignant melanoma - overview.

Authors:  Tadeusz Debniak
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

7.  Identification of driver copy number alterations in diverse cancer types and application in drug repositioning.

Authors:  Wenbin Zhou; Zhangxiang Zhao; Ruiping Wang; Yue Han; Chengyu Wang; Fan Yang; Ya Han; Haihai Liang; Lishuang Qi; Chenguang Wang; Zheng Guo; Yunyan Gu
Journal:  Mol Oncol       Date:  2017-08-03       Impact factor: 6.603

8.  The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Authors:  F Lesueur; M de Lichy; M Barrois; G Durand; J Bombled; M-F Avril; A Chompret; F Boitier; G M Lenoir; B Bressac-de Paillerets; Monique Baccard; Bertrand Bachollet; Pascaline Berthet; Valérie Bonadona; Jean-Marie Bonnetblanc; Olivier Caron; Jacqueline Chevrant-Breton; Jean-François Cuny; Stéphane Dalle; Michèle Delaunay; Liliane Demange; Julie De Quatrebarbes; Jean-François Doré; Marc Frénay; Jean-Pierre Fricker; Marion Gauthier-Villars; Paul Gesta; Sophie Giraud; Philippe Gorry; Florent Grange; Andrew Green; Laetitia Huiart; Nicolas Janin; Pascal Joly; Delphine Kérob; Christine Lasset; Dominique Leroux; Jean-Marc Limacher; Michel Longy; Sandrine Mansard; Karine Marrou; Tanguy Martin-Denavit; Christine Mateus; Eve Maubec; Laurence Olivier-Faivre; Vincent Orlandini; Pascal Pujol; Bruno Sassolas; Dominique Stoppa-Lyonnet; Luc Thomas; Pierre Vabres; Laurence Venat; Ewa Wierzbicka; Hélène Zattara
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

9.  Deficiency of PTEN and CDKN2A Tumor-Suppressor Genes in Conventional and Chondroid Chordomas: Molecular Characteristics and Clinical Relevance.

Authors:  Chenlong Yang; Jianjun Sun; Lei Yong; Chen Liang; Tie Liu; Yulun Xu; Jun Yang; Xiaoguang Liu
Journal:  Onco Targets Ther       Date:  2020-05-25       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.